Fig. 5
The photothermal capacity and anti-CRC effect of HCR NPs in vivo. A In vivo distribution of IR820, CLT-IR820, free HA + HCR NPs, and HCR NPs at various times. B In vivo thermal imaging of different groups of treated mice. (λ = 808 nm, P = 1 W/cm2; 5 min). C Schematic illustration of the tumor treatment procedure in vivo. D The volume of tumors from each group (5 mice per group) was measured at the indicated time points. E Representative images of isolated tumors. F The weight of individual tumors and the inhibition ratio. G Immunoblot analysis of apoptotic markers and PRDX2 in tumor tissues treated with vehicle, CLT-IR820 or HCR NPs intravenously through the tail vein at the end of the treatment period. (λ = 808 nm, P = 1 W/cm2; 5 min). H Representative H&E staining and Ki67 immunohistochemistry images at the end of the treatment period of mice treated with vehicle, CLT-IR820 or HCR NPs intravenously through the tail vein. Scale bar: 40 μm. (λ = 808 nm, P = 1 W/cm2; 5 min)